# Opioid Use Disorder in Adolescents: Medication-Assisted Treatment

## Overview

Adolescent opioid use disorder is a serious and potentially fatal condition that remains dramatically undertreated in youth populations. Medications for opioid use disorder, particularly buprenorphine, are evidence-based and recommended for adolescents with OUD, yet they are used far less often than the evidence warrants. The opioid crisis has disproportionately affected adolescents through prescription opioid misuse and, increasingly, through exposure to illicitly manufactured fentanyl. Fentanyl contamination of counterfeit pills and other illicit drugs has made any opioid use far more dangerous for this population. Barriers to treatment include provider reluctance to prescribe to minors, parental consent issues, limited adolescent-specific treatment programs, pervasive stigma, and historical regulatory barriers such as the X-waiver requirement, which has since been eliminated. Comprehensive treatment integrates medication-assisted approaches with psychosocial interventions and concurrent management of comorbid psychiatric conditions.

## Epidemiology

Approximately 3-5% of adolescents report past-year prescription opioid misuse, and the prevalence of OUD in this age group is estimated at 0.5-1%. Opioid overdose deaths in adolescents have increased dramatically since 2019, driven primarily by illicitly manufactured fentanyl. Common pathways to adolescent OUD include misuse of prescription opioids obtained after surgery or diverted from family members, heroin use, and ingestion of counterfeit pills containing fentanyl. Fentanyl is now implicated in the majority of adolescent opioid overdose deaths. Risk factors for developing OUD include chronic pain requiring opioid prescriptions, family history of substance use disorders, psychiatric comorbidity such as depression, ADHD, and PTSD, adverse childhood experiences, and peer substance use.

## Medications for Opioid Use Disorder (MOUD)

### Buprenorphine

Buprenorphine is the first-line medication for adolescents with moderate-to-severe OUD. It is a partial mu-opioid receptor agonist, which means it produces a ceiling effect on respiratory depression, making it substantially safer than full agonists like methadone. The FDA has approved buprenorphine for OUD treatment in individuals aged sixteen and older, though it is used off-label in younger adolescents when clinically indicated. Available formulations include sublingual tablets, sublingual film (the buprenorphine/naloxone combination marketed as Suboxone), and extended-release injectable formulations. The combination product with naloxone is generally preferred because the naloxone component deters diversion and injection misuse.

Induction requires that the patient be in mild-to-moderate opioid withdrawal to avoid precipitating withdrawal. The Clinical Opiate Withdrawal Scale score should be eight to twelve or higher before starting. A typical first-day dose is 2-4 mg of buprenorphine, titrated to 8-16 mg over two to three days, with a target maintenance dose of 8-24 mg daily, though some patients require higher doses. Micro-dosing induction protocols are emerging as alternatives that allow initiation without waiting for full withdrawal to develop.

The evidence base in adolescents is supported by the Woody et al. randomized controlled trial, which demonstrated that adolescents aged fifteen to twenty-one treated with buprenorphine/naloxone had significantly less opioid use at twelve weeks compared to those who received clonidine-assisted detoxification alone. Extended buprenorphine treatment over months to years consistently outperforms short-term detoxification followed by medication discontinuation. Relapse rates are very high after buprenorphine is stopped, and many adolescents require long-term maintenance treatment.

### Naltrexone

Naltrexone is a mu-opioid receptor antagonist that blocks opioid effects without producing any agonist activity. It is available as a daily oral formulation or as an extended-release monthly intramuscular injection. The patient must be fully detoxified, meaning seven to ten days opioid-free, before naltrexone can be initiated, because starting it earlier will precipitate withdrawal. The extended-release injectable form may be preferable for adolescents because the monthly injection schedule improves adherence compared to a daily pill. A significant limitation is that if an adolescent relapses while taking naltrexone and then discontinues the medication, their tolerance will have been lost, substantially increasing the risk of a fatal overdose.

| Feature | Buprenorphine/Naloxone | Extended-Release Naltrexone | Methadone |
|---|---|---|---|
| Mechanism | Partial mu-opioid agonist | Mu-opioid antagonist | Full mu-opioid agonist |
| FDA-Approved Age | 16+ (off-label younger) | 18+ | Restricted under 18 (requires 2 prior failures) |
| Formulations | Sublingual tablet/film | Monthly IM injection | Oral liquid (daily observed) |
| Induction Requirement | Mild-moderate withdrawal (COWS 8-12+) | Full detox (7-10 days opioid-free) | No withdrawal required |
| Typical Dose | 8-24 mg/day | 380 mg monthly | Variable (individualized) |
| Key Advantages | Office-based, ceiling effect on respiratory depression | Monthly dosing improves adherence | Longest track record |
| Key Disadvantages | Diversion risk, daily dosing | Requires full detox, overdose risk if relapse + discontinuation | OTP-only, strict regulations for minors |
| Adolescent Evidence | Woody et al. RCT (first-line) | Limited adolescent data | Very limited adolescent access |

### Methadone

Methadone is a full mu-opioid receptor agonist and the most extensively studied medication for OUD in adults. In the United States, methadone for OUD can only be dispensed through federally licensed opioid treatment programs. Federal regulations require that patients under eighteen must have failed two prior treatment attempts before methadone can be initiated, and parental consent is mandatory. These restrictions make methadone access extremely limited for adolescents in the US, though it is used more widely for adolescent OUD treatment in some international settings.

## The X-Waiver and Regulatory Changes

Previously, prescribers needed a special X-waiver under the DATA 2000 legislation to prescribe buprenorphine for OUD, and obtaining this waiver required additional training. This requirement was a significant barrier because most providers never obtained one, which severely limited access to buprenorphine treatment. The X-waiver was eliminated in January 2023 as part of the Consolidated Appropriations Act. Now any provider with a DEA license can prescribe buprenorphine for OUD without any additional waiver or training requirements. This change is expected to increase access significantly, although many providers remain hesitant to prescribe buprenorphine to adolescents due to limited training and comfort with this population.

## Parental Consent and Confidentiality Issues

Parental consent requirements for adolescent OUD treatment vary by state. Many states allow minors to consent to substance use treatment without parental involvement. However, insurance claims and pharmacy notifications may inadvertently reveal treatment to parents regardless of consent protections. Balancing confidentiality with the potential clinical benefits of family involvement requires careful clinical judgment. Best practice is to encourage voluntary parental involvement while respecting the adolescent's autonomy and applicable legal protections. For youth in foster care or involved in the juvenile justice system, consent processes become more complex and often involve additional parties.

## Barriers to MOUD for Adolescents

Multiple barriers limit adolescents' access to evidence-based medication treatment. Provider barriers include a lack of training in adolescent addiction medicine, discomfort prescribing MOUD to minors, and the persistent belief that adolescents are "too young" for maintenance therapy. Systemic barriers include the scarcity of adolescent-specific OUD treatment programs and the very limited number of child and adolescent addiction psychiatrists. Stigma remains powerful, with the misconception that MOUD simply "replaces one drug with another" persisting even within treatment communities where abstinence-only philosophies dominate. Regulatory barriers, though diminished by the elimination of the X-waiver, still include the strict methadone restrictions for minors. Family barriers include parental resistance to MOUD, a strong preference for drug-free treatment approaches, and difficulty navigating insurance systems. Adolescent-specific barriers include ambivalence about treatment, peer influences that undermine recovery, and difficulty maintaining adherence to daily dosing.

## Psychosocial Treatment Components

MOUD should always be combined with psychosocial treatment rather than used in isolation. Motivational Enhancement Therapy addresses the ambivalence about treatment and change that is characteristic of adolescents. CBT targets maladaptive coping strategies, identifies triggers, and builds relapse prevention skills. Contingency management uses tangible rewards for negative drug screens and treatment adherence. Family-based therapies, including Multidimensional Family Therapy and Brief Strategic Family Therapy, address family dynamics, improve communication, and strengthen parental monitoring. Treatment of comorbid psychiatric disorders is essential, as untreated ADHD, depression, anxiety, and PTSD are major drivers of relapse. Harm reduction measures, including naloxone distribution and education about fentanyl test strips, should be incorporated into treatment from the outset.

## Overdose Prevention

All adolescents with OUD, along with their families, should receive naloxone rescue kits and thorough education on their use. Naloxone is available as an intranasal spray and as an auto-injector. Families and patients should be educated on recognizing the signs of overdose, which include unresponsiveness, slow or absent breathing, pinpoint pupils, and blue discoloration of the lips and fingers. Because of fentanyl's extreme potency, fentanyl overdoses may require multiple naloxone doses. Naloxone should be carried by the adolescent, kept at home, and ideally available at school.

<image>A treatment algorithm for adolescent opioid use disorder. Start with assessment (DSM-5 OUD criteria, severity rating, comorbidity screen, urine drug screen). For mild OUD: consider psychosocial treatment alone (MET/CBT), with close monitoring. For moderate-to-severe OUD: initiate buprenorphine/naloxone (first-line MOUD) combined with psychosocial treatment. Show the induction process: wait for COWS score 8-12+, start 2-4 mg, titrate to 8-16+ mg. If buprenorphine is not appropriate or declined: consider extended-release naltrexone (requires full detox first). Add concurrent treatment of comorbid psychiatric disorders and naloxone distribution. Maintenance: continue MOUD for months to years; taper only when stable with shared decision-making.</image>

<image>A comparison table of MOUD options for adolescents. Columns: buprenorphine/naloxone, extended-release naltrexone, methadone. Rows: mechanism (partial agonist, antagonist, full agonist), FDA approval age (16+, 18+, restricted under 18), formulation (sublingual, monthly injection, liquid daily), induction requirements (mild withdrawal needed, full detox needed, no withdrawal needed), advantages (office-based, good safety, long track record), disadvantages (diversion risk, requires detox first, OTP restrictions), adherence (daily dosing vs. monthly injection vs. daily observed dosing). Highlight buprenorphine as first-line for adolescents.</image>

<image>An infographic on fentanyl risk in the adolescent opioid crisis. Show: the dramatic increase in adolescent opioid overdose deaths since 2019, the prevalence of fentanyl in illicit drug supply, examples of counterfeit pills that look identical to real prescription medications (M30 pills), the lethal dose comparison (2 mg of fentanyl vs. 30 mg of heroin), and the importance of naloxone rescue kit distribution. Include a call to action: every adolescent with OUD or opioid exposure should receive naloxone training.</image>

## Clinical Pearls

Buprenorphine is the first-line MOUD for adolescents with moderate-to-severe OUD and remains dramatically underutilized; the X-waiver is no longer required, removing a major historical barrier. Short-term detoxification alone, without maintenance MOUD, produces very high relapse rates in adolescents, and long-term buprenorphine maintenance is associated with substantially better outcomes. Fentanyl contamination has made any opioid use far more lethal than in previous years, and every adolescent with OUD should receive naloxone. The misconception that MOUD is "replacing one drug with another" is a persistent barrier that must be actively addressed; MOUD is evidence-based treatment that reduces overdose death, criminal activity, and infectious disease transmission. Comorbid psychiatric disorders must always be treated concurrently, as untreated depression, PTSD, and ADHD are major drivers of relapse. Federal regulations for methadone are restrictive for minors, requiring two prior treatment failures, which makes buprenorphine far more accessible in practice. Extended-release naltrexone may improve adherence in adolescents through its monthly injection schedule, but it requires full detoxification first, which can be a significant clinical barrier. Parental involvement, when possible, improves outcomes, and clinicians should encourage voluntary disclosure while respecting the legal confidentiality protections that apply.

## References
- Woody, G.E. et al. (2008). Extended vs. short-term buprenorphine-naloxone for treatment of opioid-addicted youth. *JAMA*, 300(17), 2003-2011.
- Committee on Substance Use and Prevention, AAP. (2016). Medication-assisted treatment of adolescents with opioid use disorders. *Pediatrics*, 138(3), e20161893.
- Hadland, S.E. et al. (2018). Receipt of timely addiction treatment and association of early medication treatment with retention in care among youth with opioid use disorder. *JAMA Pediatrics*, 172(11), 1029-1037.
- Tanz, L.J. et al. (2022). Drug overdose deaths among persons aged 10-19 years, United States, 2019-2021. *MMWR*, 71(50), 1576-1582.
- Matson, S.C. et al. (2014). Buprenorphine treatment for adolescent opioid use. *Current Opinion in Pediatrics*, 26(4), 449-455.
- SAMHSA. (2023). Treatment Improvement Protocol (TIP) 63: Medications for Opioid Use Disorder.